SCHEMBL6918232

SCHEMBL6918232

COC(=O)N[C@@H](Cc1cccs1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.57
CTSK P43235 3/20 0.55
CTSS P25774 1/20 0.55
RAB9A P51151 3/20 0.50
ALDH1A1 P00352 3/20 0.48
FOLH1 Q04609 2/20 0.47
CTSC P53634 1/20 0.46
PKM P14618 1/20 0.45
LMNA P02545 3/20 0.44
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPT P10636 1/20 0.44
SLC1A3 P43003 1/20 0.43
SLC1A2 P43004 1/20 0.43
SLC1A1 P43005 1/20 0.43
NPC1 O15118 1/20 0.43
CYP3A4 P08684 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL844317 0.86 CTSK (0.73) CYP2C19CTSKCTSSRAB9A
SCHEMBL2481878 0.86 CTSK (0.73) CYP2C19CTSKCTSSRAB9A
SCHEMBL844316 0.86 CTSK (0.73) CYP2C19CTSKCTSSRAB9A
SCHEMBL7362447 0.85 CYP2C19 (0.60) CYP2C19CTSKCTSSRAB9AALDH1A1
SCHEMBL7362451 0.85 CYP2C19 (0.60) CYP2C19CTSKCTSSRAB9AALDH1A1
SCHEMBL12386815 0.84 CYP2C19 (0.58) CYP2C19CTSKCTSSRAB9AALDH1A1
SCHEMBL2464520 0.83 CTSK (0.48) CYP2C19CTSKCTSSRAB9AALDH1A1
SCHEMBL2961792 0.82 CTSB (0.56) CYP2C19CTSKCTSSCYP3A4
SCHEMBL2961789 0.82 CTSB (0.56) CYP2C19CTSKCTSSCYP3A4
SCHEMBL13567542 0.82 CYP2C19 (0.60) CYP2C19CTSKCTSSRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009923-A1 Peptide analogs as irreversible interleukin-1beta protease inhibitors DOLLE ROLAND E (US) 2004-01-15 US disclosed
US-6576614-B1 Administering methyl ketones or closed hemiketal derivatives of aspartic acid VERTEX PHARMACEUTICALS INCORPORATED 2003-06-10 US disclosed
EP-0623592-B1 Peptide analogs as irreversible interleukin-1beta protease inhibitors VERTEX PHARMA (US) 2001-06-27 EP disclosed
US-5985838-A TREATING INFECTIOUS DISEASE, RESPIRATORY DISEASE, INFLAMMATORY CONDITIONS, IMMUNE-BASED DISEASE, AUTO-IMMUNE DISEASE, BONE DISEASE, AND TUMORS VERTEX PHARMACEUTICALS, INC. (US) 1999-11-16 US disclosed
EP-0623592-A1 Peptide analogs as irreversible interleukin-1beta protease inhibitors STERLING WINTHROP INC. (US) 1994-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009923-A1 Peptide analogs as irreversible interleukin-1beta protease inhibitors IL1B, IL1A, IL1RN CYP2C19 2109/4885CTSK 126/4885CTSS 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.